Mechanism of action and clinical significance of CST1 in the progression of gastric cancer

Abstract

Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492.

References28

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[2]	Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins[J].Biochem Soc Symp,2003,70: 179-199. DOI:10.1042/bss0700179.
[3]	Anastasi A, Brown MA, Kembhavi AA, et al. Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum[J].Biochem J,1983,211(1): 129-138. DOI:10.1042/bj2110129. pmid:6409085
[4]	Delimont NM, Nickel S. Salivary cystatin SN is a factor predicting iron bioavailability after phytic acid rich meals in female participants[J].Int J Food Sci Nutr,2021,72(4): 559-568. DOI:10.1080/09637486.2020.1846164.
[5]	de Sousa-Pereira P, Amado F, Abrantes J, et al. An evolutionary perspective of mammal salivary peptide families: cystatins, histatins, statherin and PRPs[J].Arch Oral Biol,2013,58(5): 451-458. DOI:10.1016/j.archoralbio.2012.12.011. pmid:23352445
[6]	Dickinson DP, Thiesse M, Dempsey LD, et al. Genomic cloning, physical mapping, and expression of human type 2 cystatin genes[J].Crit Rev Oral Biol Med,1993,4(3/4): 573-580. DOI:10.1177/10454411930040034401.
[7]	陈涛.CST1促进胃癌转移的作用及其机制研究[D]. 苏州: 苏州大学,2021. DOI:10.27351/d.cnki.gszhu.2021.001853.
[8]	Liu Y, Yao J. Research progress of cystatin SN in cancer[J].Onco Targets Ther,2019,12: 3411-3419. DOI:10.2147/OTT.S194332.
[9]	Tian S, Peng P, Li J, et al. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway[J].Aging (Albany NY),2020,12(4): 3574-3593. DOI:10.18632/aging.102831.
[10]	Bure IV, Nemtsova MV, Zaletaev DV. Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer[J].Int J Mol Sci,2019,20(12): 2870. DOI:10.3390/ijms20122870.
[11]	Cui Y, Sun D, Song R, et al. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis[J].J Cell Physiol,2019,234(12): 22623-22634. DOI:10.1002/jcp.28828. pmid:31106426
[12]	Yang J, Luo G, Li C, et al. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma[J].BMC Cancer,2022,22(1): 589. DOI:10.1186/s12885-022-09685-z. pmid:35637432
[13]	Chen S, Liu Y, Zhang K, et al. CST1 promoted gastric cancer migration and invasion through activating Wnt pathway[J].Cancer Manag Res,2021,13: 1901-1907. DOI:10.2147/CMAR.S277770. pmid:33658852
[14]	Taciak B, Pruszynska I, Kiraga L, et al. Wnt signaling pathway in development and cancer[J].J Physiol Pharmacol,2018,69(2): 185-196. DOI:10.26402/jpp.2018.2.07.
[15]	Clements WM, Wang J, Sarnaik A, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer[J].Cancer Res,2002,62(12): 3503-3506. pmid:12067995
[16]	Kang MH, Choi H, Oshima M, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer[J].Nat Commun,2018,9(1): 1920. DOI:10.1038/s41467-018-04244-2.
[17]	Fang J, Wang J, Yu L, et al. Role of HOXC10 in cancer[J].Front Oncol,2021,11: 684021. DOI:10.3389/fonc.2021.684021.
[18]	Keppler D, Zhang J, Bihani T, et al. Novel expression of CST1 as candidate senescence marker[J].J Gerontol A Biol Sci Med Sci,2011,66(7): 723-731. DOI:10.1093/gerona/glr033.
[19]	Peng Y, Li Y, Li Y, et al. HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer[J].Aging (Albany NY),2020,12(19): 19375-19398. DOI:10.18632/aging.103824.
[20]	Zhang X, Zheng Y, Liu X, et al. The expression of HOXC10 is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker[J].Ann Transl Med,2022,10(2): 81. DOI:10.21037/atm-21-6611.
[21]	Kim J, Bae DH, Kim JH, et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer[J].Oncol Rep,2019,42(1): 202-212. DOI:10.3892/or.2019.7164. pmid:31115563
[22]	Xu C, Liu Z, Xiao J. Ferroptosis: a double-edged sword in gastrointestinal disease[J].Int J Mol Sci,2021,22(22): 12403. DOI:10.3390/ijms222212403.
[23]	Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis[J].Proteomics,2019,19(18): e1800311. DOI:10.1002/pmic.201800311.
[24]	Zhao L, Peng Y, He S, et al. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer[J].Gastric Cancer,2021,24(3): 642-654. DOI:10.1007/s10120-021-01159-8. pmid:33544270
[25]	Li D, Wang Y, Dong C, et al. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stabi-lity via OTUB1[J].Oncogene,2023,42(2): 83-98. DOI:10.1038/s41388-022-02537-x.
[26]	王宁宁, 孙明军, 田百玲. miRNA在Hp感染相关胃癌中作用的研究进展[J].山东医药,2019,59(10): 93-96. DOI:10.3969/j.issn.1002-266X.2019.10.027.
[27]	陶清.胃癌上皮间质转化关键基因TNS1的识别和验证及临床关联研究[D]. 镇江: 江苏大学,2020. DOI:10.27170/d.cnki.gjsuu.2020.000957.
[28]	Choi EH, Kim JT, Kim JH, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer[J].Clin Chim Acta,2009,406(1/2): 45-51. DOI:10.1016/j.cca.2009.05.008.

Mechanism of action and clinical significance of CST1 in the progression of gastric cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References28

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341.
[6]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[7]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185.
[8]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.
[9]	Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86.
[10]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[11]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682.
[12]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.
[13]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281.
[14]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun.Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728.
[15]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50.